The Melanoma Nursing Initiative – Home › Forums › Targeted therapy › Dosing and administration › New BRAF/MEK inhibitors coming to market › Reply To: New BRAF/MEK inhibitors coming to market
October 7, 2018 at 6:19 am #4899
Expert NurseKathleen Madden
This past week I have had 2 more patients on Braf/Mek- tovi’s experience febrile toxicities preceeded by several days of mild anorexia. While the drugs were placed on hold, some of the symptoms proceeded to get worse or persist about 3-5 days later, I am attributing this to the long half life. Febrile work ups have been negative, no other clinical sx of infection. Low dose steroids have been most effective for these cases.
Next step plan is to get to back to baseline & dose reduce & restart.
Any similar experiences?